COVID-19 Resources from SITC
As the world responds to the coronavirus (COVID-19) pandemic, the oncology and immuno-oncology communities may face unique challenges in regards to patient care. It has also become apparent that the immunotherapy field may offer important insights that can be useful to the broader healthcare community during this time of need.
SITC is committed to providing important COVID-19 information for immuno-oncology professionals. Recently, the society launched an online COVID-19 resource hub that provides timely informational and essential tools as well as discussion forums tailored to both practicing clinicians and laboratory researchers in the immuno-oncology community.
Please consider participating in SITC's COVID-19 discussion forums for real-time sharing of observations and insights regarding basic and translational science related to SARS-CoV-2 and the clinical management of patients with COVID-19. You need not be a SITC member to access and post in these discussion forums; all are encouraged to participate. Simply create a free CONNECT online account when prompted. Access all of SITC's online COVID-19 resources, including the discussion forums, here.
SITC to host 35th Anniversary Meeting on Nov. 10–15
Member Registration and Housing is Now Open
SITC will welcome researchers, clinicians and others from around the cancer immunotherapy field to the 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) in November! Taking place on new days this fall, SITC 2020 begins on Tuesday, Nov. 10 through Sunday, Nov. 15, 2020, at the Gaylord National Hotel & Convention Center in National Harbor, Md.
SITC student members will receive free registration in celebration of our anniversary year, and all other SITC members receive discounted, early access to registration beginning today. Once registered, attendees will be able to secure housing for the conference. Registration and housing opens to the general public on April 20. Click here to learn more about SITC 2020 registration and how to renew your membership to guarantee you early access to registration and housing.
Regular Abstract Submission and Late-Breaking Abstract Applications Now Open
SITC has begun accepting submissions of regular abstracts and late-breaking abstract applications for the 35th Anniversary Annual Meeting beginning. Present your work to the world's largest scientific conference dedicated solely to cancer immunotherapy! Click here to learn more about submission requirements.
Young Investigator Awards
In celebration of the society's 35th anniversary of advancing cancer immunotherapy worldwide, SITC will present 35 travel awards to young investigators recognizing excellence in novel research, providing young investigators with the experience necessary for successful careers and acknowledging the need for the next generation of cancer immunologists to engage with luminaries in the field. All awards are supported by the Forward Fund.
Regular abstracts with primary and presenting authors that are students, postdoctoral research fellows, clinical fellows, or junior faculty with three or fewer years on staff and are current SITC members, may be eligible to receive a Young Investigator Award. Young Investigator Award abstracts require a letter of recommendation as well as additional information regarding the percentage of contribution by the primary and presenting author. For more information about the Young Investigator Awards as well as the criteria and eligibility, please click here.
Thank You to Our SITC 2020 Organizers
Annual Program Committee Chair
- Sandra Demaria, MD – Weill Cornell Medicine
35th Anniversary Annual Meeting Organizers
- Helen E. Heslop, MD – Baylor College of Medicine
- Brianna W. Hoffner, MSN, ANP-BC, AOCNP – Harborside
- Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai
- Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
- Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
35th Anniversary Annual Meeting Program Committee Members
- Ana Carrizosa Anderson, PhD – Harvard Medical School
- Davide Bedognetti, MD, PhD – Sidra Medicine
- Marianne Davies, DNP, AOCNP – Yale School of Nursing
- Patrick Hwu, MD – The University of Texas MD Anderson Cancer Center
Immunotherapy Resistance and Failure
- Kald Abdallah, MD, PhD– Bristol-Myers Squibb
- Edward Cha, MD, PhD – Genentech
- Leena Gandhi, MD, PhD – Eli Lilly
- Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
Primer on Tumor Immunology and Cancer Immunotherapy™
- Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
- Yvonne Saenger, MD – Columbia University Irving Medical Center
Workshop on Engineering Immune Cells for Cancer Therapy
- Christine Brown, PhD – City of Hope
- Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
- Marco Ruella, MD – University of Pennsylvania
Grant Writing Workshop
- David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center
- Olivia Rongze Lu, PhD – University of Texas at Austin
- Claire Vanpouille-Box, PhD – Weill Cornell Medical College
- Grey Wilkinson, PhD – Oncolytics Biotech Inc.
SITC Immunotherapy Resistance Definitions
In Spring 2019, SITC convened key stakeholders from academia, industry, government, and other like-minded societies in order to form expert consensus definitions for clinical resistance to PD-(L)1 checkpoint inhibitors. This highly successful meeting resulted in the recent publication of "Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce," in the Journal for Immunotherapy of Cancer (JITC). This important manuscript details resistance definitions in three clinical scenarios—primary resistance, secondary resistance, and progression after discontinuation of treatment—as well as suggests next steps the field should take in order to standardize data collection on immunotherapy resistance and advance clinical drug development. We look forward to these resistance definitions being incorporated into future immunotherapy clinical trials.
SITC views the topic of immunotherapy resistance as a priority for the society, and this workshop and manuscript are only the first steps. In order to continue the momentum of the meeting and subsequent publication, SITC recently formed an Immunotherapy Resistance Committee, whose primary charge is to expand definitions of resistance to other immunotherapy regimens, as well as to engage stakeholders concerning data sharing and accessibility to validate the generated definitions. This committee looks forward to continuing this important work on immunotherapy resistance to help advance the field and provide benefit to patients.
For more on this topic, view a presentation from Ryan J. Sullivan, MD, during SITC 2019's Update on the SITC PD-(L)1 Resistance Definitions: https://www.sitcancer.org/viewdocument/sitc-2019-annual-meeting-session-3
2020 SITC Fellowship and Award Opportunities
Become a SITC member or renew your membership to grow your professional network, receive discounted registration rates to exemplary meetings, early access to housing and remain current with the field of cancer immunotherapy.
Join the SITC family or renew your membership today!